Nye Gordon E 4
4 · REVA Medical, Inc. · Filed Dec 20, 2010
Insider Transaction Report
Form 4
Nye Gordon E
Director
Transactions
- Conversion
Common Stock
2010-12-16+122,951→ 782,125 total - Exercise of In-Money
Common Stock
2010-12-16$6.51/sh+464$3,019→ 823,531 total - Conversion
Series C Preferred Stock
2010-12-16−31,726→ 0 total→ Common Stock (31,726 underlying) - Conversion
Common Stock
2010-12-16+3,930→ 575,365 total - Conversion
Common Stock
2010-12-16+38,621→ 820,746 total - Conversion
Series B Preferred Stock
2010-12-16−52,083→ 0 total→ Common Stock (52,083 underlying) - Conversion
Series D Preferred Stock
2010-12-16−122,951→ 0 total→ Common Stock (122,951 underlying) - Exercise of In-Money
Common Stock
2010-12-16$6.51/sh+2,321$15,102→ 823,067 total - Conversion
Series A Preferred Stock
2010-12-16−3,930→ 0 total→ Common Stock (3,930 underlying) - Conversion
Series H Preferred Stock
2010-12-16−34,295→ 0 total→ Common Stock (34,295 underlying) - Exercise of In-Money
Warrant
2010-12-16$6.51/sh−5,716$37,192→ 0 totalExercise: $6.51From: 2010-05-25Exp: 2012-12-07→ Common Stock (5,716 underlying) - Conversion
Common Stock
2010-12-16+52,083→ 627,448 total - Exercise of In-Money
Warrant
2010-12-16$6.51/sh−1,143$7,437→ 0 totalExercise: $6.51From: 2010-06-02Exp: 2012-12-07→ Common Stock (1,143 underlying) - Conversion
Common Stock
2010-12-16+31,726→ 659,174 total
Footnotes (3)
- [F1]Each outstanding share of the Issuer's Preferred Stock automatically converted to one share of Common Stock upon the closing of the Issuer's initial public offering.
- [F2]Includes 4,326 shares of Series H Preferred Stock which were accrued as cumulative dividends and paid upon the closing of the Issuer's initial public offering on as-converted basis.
- [F3]Represents the issuance of Common Stock upon the exercise of such warrant on a cashless basis upon the closing of the Issuer's initial public offering.